COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1(RAPA-201) Cell Therapy of Relapsed, Refractory Multiple Myeloma

Protocol No
RAPA-201-RRMM
Principal Investigator
Binod Dhakal
Phase
II
Summary
To find out more about an investigational therapy, RAPA-201 cells, in patients with relapsed, refractory multiple myeloma (RRMM).
Description
RAPA-201 T Cell Therapy for RR MM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL